OCULAR THERAPEUTIX, INC Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
OCULAR THERAPEUTIX, INC (OCUL) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -1.90% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-05
- OCULAR THERAPEUTIX, INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was -1.90%.
- OCULAR THERAPEUTIX, INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was -2.30%.
- OCULAR THERAPEUTIX, INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was -2.10%.
- OCULAR THERAPEUTIX, INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2021 was -7.80%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | -1.90% 10-K · filed 2026-02-05 | |
| 2023-12-31 | -2.30% 10-K · filed 2026-02-05 | |
| 2022-12-31 | -2.10% 10-K · filed 2025-03-03 | |
| 2021-12-31 | -7.80% 10-K · filed 2024-03-11 | |
| 2019-12-31 | -1.30% 10-K · filed 2022-02-28 | |
| 2018-12-31 | -1.30% 10-K · filed 2020-03-12 | |
| 2017-12-31 | -2.20% 10-K · filed 2020-03-12 | |
| 2016-12-31 | -1.40% 10-K · filed 2019-03-07 | 1.40% 10-K · filed 2017-03-10 |
| 2015-12-31 | -1.20% 10-K · filed 2018-03-08 | 1.20% 10-K · filed 2016-03-10 |
| 2014-12-31 | 1.60% 10-K · filed 2017-03-10 | |
| 2013-12-31 | 1.30% 10-K · filed 2016-03-10 | |
| 2012-12-31 | 0.30% 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |